T1	Participants 39 119	previously treated patients with refractory advanced non-small-cell lung cancer:
T2	Participants 374 445	patients with locally advanced or metastatic non-small-cell lung cancer
T3	Participants 455 542	1692 patients who were refractory to or intolerant of their latest chemotherapy regimen
T4	Participants 942 996	1129 patients were assigned gefitinib and 563 placebo.